A Phase I/ II Trial of Pazopanib Alternating With Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients
Phase of Trial: Phase I/II
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Pazopanib (Primary) ; Bevacizumab
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 19 Feb 2018 Planned primary completion date changed from 5 Feb 2018 to 5 May 2018.
- 28 Nov 2017 Planned number of patients changed from 66 to 35.
- 10 Jun 2017 Biomarkers information updated